Fig. 3From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from ChinaCA125 in patients with different BRCA status in the first-line maintenance group. Note: Two patients with BRCA mutation in the first-line maintenance treatment group was followed up with CA125Back to article page